Utility of the apparent diffusion coefficient for distinguishing clear cell renal cell carcinoma of low and high nuclear grade

American Journal of Roentgenology

Volumn 195, Issue 5, 2010, Pages

  Rosenkrantz, Andrew B ^a   Niver, Benjamin E ^a   Fitzgerald, Erin F ^a   Babb, James S ^a   Chandarana, Hersh ^a   Melamed, Jonathan ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apparent diffusion coefficient (ADC); Clear cell renal cell carcinoma; Diffusion weighted imaging; Fuhrman nuclear grade; Renal MRI

Indexed keywords

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 78649690893     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4688     Document Type: Article

References (74)

1. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51:203-205
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281:1628-1631 (Pubitemid 29211773)
3. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006; 176:2397-2400; discussion, 2400
4. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am 2008; 35:627-634; vii
5. Kummerlin IP, ten Kate FJ, Wijkstra H, de la Rosette JJ, Laguna MP. Changes in the stage and surgical management of renal tumours during 1995-2005: an analysis of the Dutch national histopathology registry. BJU Int 2008; 102:946-951
6. Sanchez-Martin FM, Millan-Rodriguez F, Urdaneta-Pignalosa G, Rubio-Briones J, Villavicencio-Mavrich H. Small renal masses: incidental diagnosis, clinical symptoms, and prognostic factors. Adv Urol 2008; 310694
7. Kutikov A, Kunkle DA, Uzzo RG. Focal therapy for kidney cancer: a systematic review. Curr Opin Urol 2009; 19:148-153
8. Stern JM, Svatek R, Park S, et al. Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. BJU Int 2007; 100:287-290
9. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol 2008; 180:505-508; discussion 508-509
10. Berger A, Crouzet S, Canes D, Haber GP, Gill IS. Minimally invasive nephron-sparing surgery. Curr Opin Urol 2008; 18:462-466
11. Heldwein FL, McCullough TC, Souto CA, Galiano M, Barret E. Localized renal cell carcinoma management: an update. Int Braz J Urol 2008; 34:676-689; discussion, 689-690
12. Hui GC, Tuncali K, Tatli S, Morrison PR, Silverman SG. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 2008; 19:1311-1320
13. Boorjian SA, Uzzo RG. The evolving management of small renal masses. Curr Oncol Rep 2009; 11:211-217
14. Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009; 7:635-642; quiz, 643
15. Ghoneim IA, Fergany AF. Minimally invasive surgery for renal cell carcinoma. Expert Rev Anticancer Ther 2009; 9:989-997
16. Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010; 57:223-232
17. Kunkle DA, Kutikov A, Uzzo RG. Management of small renal masses. Semin Ultrasound CT MR 2009; 30:352-358
18. Trinh QD, Saad F, Lattouf JB. The current management of small renal masses. Curr Opin Support Palliat Care 2009; 3:180-185
19. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol 2008; 26:555-559
20. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-663 (Pubitemid 13234762)
21. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma: prognostic significance of morphologic parameters in 121 cases. Cancer 1988; 61:1639-1651
22. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995; 76:2543-2549
23. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166:453-456 (Pubitemid 32652222)
24. Ficarra V, Righetti R, Martignoni G, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 2001; 67:130-134
25. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol 2005; 48:593-600
26. Minardi D, Lucarini G, Mazzucchelli R, et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol 2005; 174:1208-1212
27. Al-Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 2003; 127:593-596 (Pubitemid 36534945)
28. Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005; 103:68-75 (Pubitemid 39665458)
29. Lang H, Lindner V, de Fromont M, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. Cancer 2005; 103:625-629
30. Letourneux H, Lindner V, Lang H, et al. Reproducibility of Fuhrman nuclear grade: advantages of a two-grade system [in French]. Prog Urol 2006; 16:281-285
31. Bektas S, Bahadir B, Kandemir NO, Barut F, Gul AE, Ozdamar SO. Intraobserver and interobserver variability of Fuhrman and modified Fuhrman grading systems for conventional renal cell carcinoma. Kaohsiung J Med Sci 2009; 25:596-600
32. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol 2009; 22[suppl 2]:S24-S36
33. Pedrosa I, Chou MT, Ngo L, et al. MR classification of renal masses with pathologic correlation. Eur Radiol 2008; 18:365-375
34. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008; 27:132-139
35. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9:53-60
36. Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002; 44:656-666
37. Bulakbasi N, Guvenc I, Onguru O, Erdogan E, Tayfun C, Ucoz T. The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. J Comput Assist Tomogr 2004; 28:735-746 (Pubitemid 39489910)
38. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 2007; 13:2897-2904 (Pubitemid 46849564)
39. Alvarez-Linera J, Benito-Leon J, Escribano J, Rey G. Predicting the histopathological grade of cerebral gliomas using high b value MR DW imaging at 3-tesla. J Neuroimaging 2008; 18:276-281
40. Murakami R, Hirai T, Kitajima M, et al. Magnetic resonance imaging of pilocytic astrocytomas: usefulness of the minimum apparent diffusion coefficient (ADC) value for differentiation from high-grade gliomas. Acta Radiol 2008; 49:462-467 (Pubitemid 351598803)
41. Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 2009; 94:87-96
42. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28:720-726
43. Gauvain KM, McKinstry RC, Mukherjee P, et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR 2001; 177:449-454
44. Nonomura Y, Yasumoto M, Yoshimura R, et al. Relationship between bone marrow cellularity and apparent diffusion coefficient. J Magn Reson Imaging 2001; 13:757-760
45. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26:281-291
46. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002; 224:177-183
47. Mishra AM, Gupta RK, Saksena S, et al. Biological correlates of diffusivity in brain abscess. Magn Reson Med 2005; 54:878-885 (Pubitemid 41457059)
48. Manenti G, Di Roma M, Mancino S, et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med 2008; 113:199-213 (Pubitemid 351666954)
49. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44:572-576
50. Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 2009; 29:1360-1366
51. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-888
52. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 2007; 188:1622-1635
53. Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009; 251:838-845
54. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241:839-846 (Pubitemid 46190551)
55. Garcia-Perez AI, Lopez-Beltran EA, Kluner P, Luque J, Ballesteros P, Cerdan S. Molecular crowding and viscosity as determinants of translational diffusion of metabolites in subcellular organelles. Arch Biochem Biophys 1999; 362:329-338 (Pubitemid 29394363)
56. 2. AJR 2010; 194:172; [web] W33-W37
57. Girometti R, Furlan A, Esposito G, et al. Relevance of b-values in evaluating liver fibrosis: a study in healthy and cirrhotic subjects using two single-shot spin-echo echo-planar diffusion-weighted sequences. J Magn Reson Imaging 2008; 28:411-419
58. Coenegrachts K, Delanote J, Ter Beek L, et al. Evaluation of true diffusion, perfusion factor, and apparent diffusion coefficient in non-necrotic liver metastases and uncomplicated liver hemangiomas using black-blood echo planar imaging. Eur J Radiol 2009; 69:131-138
59. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging - pilot study. Radiology 2008; 249:891-899
60. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210:617-623
61. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 2007; 31:957-960 (Pubitemid 47165152)
62. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32:590-595
63. Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan T, Delahunt B. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 2006; 30: 1091-1096
64. True LD. The time for accurate Fuhrman grading of renal cell carcinomas has arrived. Am J Clin Pathol 2002; 118:827-829
65. Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 2002; 118:877-886 (Pubitemid 37047828)
66. Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma: can the 2002 primary tumor classification be improved? J Urol 2005; 173:716-719
67. Klatte T, Pantuck AJ, Riggs SB, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007; 178:1189-1195; discussion, 1195 (Pubitemid 47368397)
68. Pflanz S, Brookman-Amissah S, Roigas J, Kendel F, Hoschke B, May M. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol 2008; 42:507-513
69. Zubac DP, Bostad L, Gestblom C, et al. Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy. Scand J Urol Nephrol 2007; 41:191-197 (Pubitemid 46676358)
70. Bedke J, Pritsch M, Buse S, et al. Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol 2008; 180:62-67
71. Hsu RM, Chan DY, Siegelman SS. Small renal cell carcinomas: correlation of size with tumor stage, nuclear grade, and histologic subtype. AJR 2004; 182:551-557
72. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology 2007; 39:459-465 (Pubitemid 47450591)
73. Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes - correlation with pathologic findings. Radiology 2009; 250: 793-802
74. Steens SC, Admiraal-Behloul F, Schaap JA, et al. Reproducibility of brain ADC histograms. Eur Radiol 2004; 14:425-430